Literature DB >> 17901295

Effect of long-term heart rate reduction by If current inhibition on pressure overload-induced heart failure in rats.

Vlad Ciobotaru1, Michèle Heimburger, Liliane Louedec, Christophe Heymes, Renée Ventura-Clapier, Pierre Bedossa, Brigitte Escoubet, Jean-Baptiste Michel, Jean-Jacques Mercadier, Damien Logeart.   

Abstract

We investigated the effects of long-term heart rate reduction (HRR) on pressure overload-induced heart failure. Pressure overload of the left ventricle was induced in 21-day-old rats by banding the ascending aorta. HRR was induced for 3 months with ivabradine (n = 44), a selective I(f) current inhibitor, at 10 mg/kg/day, starting 14 days after banding. Thirty-six control banded rats and 16 sham-operated rats received standard chow. Banding resulted in severe left ventricular (LV) hypertrophy (+55% versus shams; p < 0.001) and fibrosis, together with a 34% decrease (p < 0.01) in the LV shortening fraction. Heart rate decreased by 19% in ivabradine-treated rats (p < 0.005 versus controls). Stroke volume increased (by 17%; p < 0.01), whereas cardiac output did not change with HRR. In contrast, HRR resulted in 1) a marked increase in LV filling pressure (p < 0.01) and in atrial, lung, and right ventricular weights (38, 30, and 54%, respectively; p < 0.001); 2) a 50% increase in the incidence of pleural/abdominal effusion (p < 0.001); 3) 7 and 26% increases in LV hypertrophy and fibrosis, respectively (p < 0.05); and 4) a 53% increase in the atrial natriuretic peptide mRNA level compared with controls (p < 0.001). After 3 months of treatment, ivabradine withdrawal normalized the heart rate and reduced LV size and LV filling pressure (p < 0.05). In conclusion, pure longstanding HRR showed no beneficial effect on LV dysfunction in a rat model of pressure overload-induced LV hypertrophy, and it seemed to favor adverse LV remodeling and its congestive consequences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17901295     DOI: 10.1124/jpet.107.130237

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.

Authors:  Jan-Christian Reil; Mathias Hohl; Gert-Hinrich Reil; Henk L Granzier; Mario T Kratz; Andrey Kazakov; Peter Fries; Andreas Müller; Matthias Lenski; Florian Custodis; Stefan Gräber; Gerd Fröhlig; Paul Steendijk; Hans-Ruprecht Neuberger; Michael Böhm
Journal:  Eur Heart J       Date:  2012-07-24       Impact factor: 29.983

2.  Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine.

Authors:  Deep Chandh Raja; Aditya Kapoor; Archana Sinha; Shiridhar Kashyap; Roopali Khanna; Sudeep Kumar; Naveen Garg; Satyendra Tewari; Pravin Goel
Journal:  Indian Heart J       Date:  2017-08-16

3.  Effect of Ivabradine on a Hypertensive Heart and the Renin-Angiotensin-Aldosterone System in L-NAME-Induced Hypertension.

Authors:  Fedor Simko; Tomas Baka; Marko Poglitsch; Kristina Repova; Silvia Aziriova; Kristina Krajcirovicova; Stefan Zorad; Michaela Adamcova; Ludovit Paulis
Journal:  Int J Mol Sci       Date:  2018-10-03       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.